PHARMACEUTICAL COMPOSITION COMPRISING GLUTATIONE DISULFIDE AND GLUTATHIONE DISULFIDE S-OXIDE

PHARMACEUTICAL COMPOSITION COMPRISING GLUTATIONE DISULFIDE AND GLUTATHIONE DISULFIDE S-OXIDE

or pharmaceutically acceptable organic or inorganic salt thereof for eliminating dose-related toxicity and enhancing the therapeutic activity of a pharmacologically active compound in the treatment of infectious and non-infectious diseases is provided. Typically, the composition comprises glutathion...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: IGNATENKO, Oleg Aleksandrovich, ANTONOV, Viktor Georgievich, BALAZOVSKIJ, Mark Borisovich
Format: Patent
Sprache:eng ; fre ; ger
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator IGNATENKO, Oleg Aleksandrovich
ANTONOV, Viktor Georgievich
BALAZOVSKIJ, Mark Borisovich
description or pharmaceutically acceptable organic or inorganic salt thereof for eliminating dose-related toxicity and enhancing the therapeutic activity of a pharmacologically active compound in the treatment of infectious and non-infectious diseases is provided. Typically, the composition comprises glutathione disulfide S-oxide in an amount of 0.01-10% by weight of the total composition, and additionally a metal (Me) in the form of coordination compound(s) containing Me-S-glutathione bond, said metal is selected from the platinum group, typically it is platinum. The amount of d-metal coordination compound administered to a patient can be 10−3 to 10−15 mol/kg of body weight. The composition can be used in combination with pharmacologically active compound, which is an anticoagulant, factor Xa inhibitor, antimicrobial or antiviral agents to increase their therapeutic activity and eliminate dose-related toxicity.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_EP3600557A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EP3600557A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_EP3600557A13</originalsourceid><addsrcrecordid>eNrjZIgJ8HAM8nV0dg0N8XR29FFw9vcN8A_2DPH09wOzgzyDPf3cFdx9QkMcQYKuCi6ewaE-bp4urgqOfi5QCQ80mWBd_wggzcPAmpaYU5zKC6W5GRTcXEOcPXRTC_LjU4sLEpNT81JL4l0DjM0MDExNzR0NjYlQAgCkQjJv</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>PHARMACEUTICAL COMPOSITION COMPRISING GLUTATIONE DISULFIDE AND GLUTATHIONE DISULFIDE S-OXIDE</title><source>esp@cenet</source><creator>IGNATENKO, Oleg Aleksandrovich ; ANTONOV, Viktor Georgievich ; BALAZOVSKIJ, Mark Borisovich</creator><creatorcontrib>IGNATENKO, Oleg Aleksandrovich ; ANTONOV, Viktor Georgievich ; BALAZOVSKIJ, Mark Borisovich</creatorcontrib><description>or pharmaceutically acceptable organic or inorganic salt thereof for eliminating dose-related toxicity and enhancing the therapeutic activity of a pharmacologically active compound in the treatment of infectious and non-infectious diseases is provided. Typically, the composition comprises glutathione disulfide S-oxide in an amount of 0.01-10% by weight of the total composition, and additionally a metal (Me) in the form of coordination compound(s) containing Me-S-glutathione bond, said metal is selected from the platinum group, typically it is platinum. The amount of d-metal coordination compound administered to a patient can be 10−3 to 10−15 mol/kg of body weight. The composition can be used in combination with pharmacologically active compound, which is an anticoagulant, factor Xa inhibitor, antimicrobial or antiviral agents to increase their therapeutic activity and eliminate dose-related toxicity.</description><language>eng ; fre ; ger</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2020</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20200205&amp;DB=EPODOC&amp;CC=EP&amp;NR=3600557A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,309,781,886,25569,76552</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20200205&amp;DB=EPODOC&amp;CC=EP&amp;NR=3600557A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>IGNATENKO, Oleg Aleksandrovich</creatorcontrib><creatorcontrib>ANTONOV, Viktor Georgievich</creatorcontrib><creatorcontrib>BALAZOVSKIJ, Mark Borisovich</creatorcontrib><title>PHARMACEUTICAL COMPOSITION COMPRISING GLUTATIONE DISULFIDE AND GLUTATHIONE DISULFIDE S-OXIDE</title><description>or pharmaceutically acceptable organic or inorganic salt thereof for eliminating dose-related toxicity and enhancing the therapeutic activity of a pharmacologically active compound in the treatment of infectious and non-infectious diseases is provided. Typically, the composition comprises glutathione disulfide S-oxide in an amount of 0.01-10% by weight of the total composition, and additionally a metal (Me) in the form of coordination compound(s) containing Me-S-glutathione bond, said metal is selected from the platinum group, typically it is platinum. The amount of d-metal coordination compound administered to a patient can be 10−3 to 10−15 mol/kg of body weight. The composition can be used in combination with pharmacologically active compound, which is an anticoagulant, factor Xa inhibitor, antimicrobial or antiviral agents to increase their therapeutic activity and eliminate dose-related toxicity.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2020</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZIgJ8HAM8nV0dg0N8XR29FFw9vcN8A_2DPH09wOzgzyDPf3cFdx9QkMcQYKuCi6ewaE-bp4urgqOfi5QCQ80mWBd_wggzcPAmpaYU5zKC6W5GRTcXEOcPXRTC_LjU4sLEpNT81JL4l0DjM0MDExNzR0NjYlQAgCkQjJv</recordid><startdate>20200205</startdate><enddate>20200205</enddate><creator>IGNATENKO, Oleg Aleksandrovich</creator><creator>ANTONOV, Viktor Georgievich</creator><creator>BALAZOVSKIJ, Mark Borisovich</creator><scope>EVB</scope></search><sort><creationdate>20200205</creationdate><title>PHARMACEUTICAL COMPOSITION COMPRISING GLUTATIONE DISULFIDE AND GLUTATHIONE DISULFIDE S-OXIDE</title><author>IGNATENKO, Oleg Aleksandrovich ; ANTONOV, Viktor Georgievich ; BALAZOVSKIJ, Mark Borisovich</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_EP3600557A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; ger</language><creationdate>2020</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>IGNATENKO, Oleg Aleksandrovich</creatorcontrib><creatorcontrib>ANTONOV, Viktor Georgievich</creatorcontrib><creatorcontrib>BALAZOVSKIJ, Mark Borisovich</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>IGNATENKO, Oleg Aleksandrovich</au><au>ANTONOV, Viktor Georgievich</au><au>BALAZOVSKIJ, Mark Borisovich</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>PHARMACEUTICAL COMPOSITION COMPRISING GLUTATIONE DISULFIDE AND GLUTATHIONE DISULFIDE S-OXIDE</title><date>2020-02-05</date><risdate>2020</risdate><abstract>or pharmaceutically acceptable organic or inorganic salt thereof for eliminating dose-related toxicity and enhancing the therapeutic activity of a pharmacologically active compound in the treatment of infectious and non-infectious diseases is provided. Typically, the composition comprises glutathione disulfide S-oxide in an amount of 0.01-10% by weight of the total composition, and additionally a metal (Me) in the form of coordination compound(s) containing Me-S-glutathione bond, said metal is selected from the platinum group, typically it is platinum. The amount of d-metal coordination compound administered to a patient can be 10−3 to 10−15 mol/kg of body weight. The composition can be used in combination with pharmacologically active compound, which is an anticoagulant, factor Xa inhibitor, antimicrobial or antiviral agents to increase their therapeutic activity and eliminate dose-related toxicity.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; fre ; ger
recordid cdi_epo_espacenet_EP3600557A1
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title PHARMACEUTICAL COMPOSITION COMPRISING GLUTATIONE DISULFIDE AND GLUTATHIONE DISULFIDE S-OXIDE
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T12%3A45%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=IGNATENKO,%20Oleg%20Aleksandrovich&rft.date=2020-02-05&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EEP3600557A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true